Recursion Pharmaceuticals, Inc.
https://www.recursion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Recursion Pharmaceuticals, Inc.
Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study
The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Recursion Pharmaceuticals, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice